Use of botulinum toxin for rosacea: a pilot study
Introduction: Rosacea is a chronic inflammatory skin disease. The intradermal application of botulinum toxin (BT) has been studied as a therapeutic option for patients who struggle to manage flushing and/or persistent facial erythema. There is no standard protocol for BT application in rosacea....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Dermatologia (SBD)
2021-12-01
|
| Series: | Surgical & Cosmetic Dermatology |
| Subjects: | |
| Online Access: | http://www.surgicalcosmetic.org.br/Content/imagebank/pdf/v13/en_v13a19.pdf |
| _version_ | 1797895024697933824 |
|---|---|
| author | Jaqueline Barbeito de Vasconcellos Isabele Oliveira Santos Daniela Alves Pereira Antelo |
| author_facet | Jaqueline Barbeito de Vasconcellos Isabele Oliveira Santos Daniela Alves Pereira Antelo |
| author_sort | Jaqueline Barbeito de Vasconcellos |
| collection | DOAJ |
| description | Introduction: Rosacea is a chronic inflammatory skin disease. The intradermal application of botulinum toxin (BT) has been studied as a therapeutic option for patients who struggle to manage flushing and/or persistent facial erythema. There is no standard protocol for BT application in rosacea.
Objective: To evaluate the effectiveness of botulinum toxin application on erythematotelan-giectatic rosacea.
Methods: Pilot study with case series. We applied intradermal BT in 10 patients with a diagnosis of rosacea and symptoms of persistent erythema and/or facial flushing. Patients received 10 to 15 injections per hemiface (1 unit of onabotulinum BT per injection) and 0 to 5 injections in the nasal region, totaling 25 to 35 units per patient.
Results: Seventy-five percent of the patients presented a reduction in flush and erythema intensity. The follow-up time was three months, and no serious adverse events were observed.
Conclusions: The therapeutic arsenal to control erythema and facial flushing of rosacea, especially refractory to the usual treatment, should consider the intradermal application of BT type A. |
| first_indexed | 2024-04-10T07:18:45Z |
| format | Article |
| id | doaj.art-a229f16532264188b05ff8c4e6680a37 |
| institution | Directory Open Access Journal |
| issn | 1984-8773 |
| language | English |
| last_indexed | 2024-04-10T07:18:45Z |
| publishDate | 2021-12-01 |
| publisher | Sociedade Brasileira de Dermatologia (SBD) |
| record_format | Article |
| series | Surgical & Cosmetic Dermatology |
| spelling | doaj.art-a229f16532264188b05ff8c4e6680a372023-02-24T17:14:06ZengSociedade Brasileira de Dermatologia (SBD)Surgical & Cosmetic Dermatology1984-87732021-12-011310.5935/scd1984-8773.2021130019Use of botulinum toxin for rosacea: a pilot studyJaqueline Barbeito de Vasconcellos0Isabele Oliveira Santos1Daniela Alves Pereira Antelo2Universidade do Estado do Rio de Janeiro, Dermatology Service, Rio de Janeiro (RJ), BrazilUniversidade do Estado do Rio de Janeiro, Dermatology Service, Rio de Janeiro (RJ), BrazilUniversidade do Estado do Rio de Janeiro, Dermatology Service, Rio de Janeiro (RJ), BrazilIntroduction: Rosacea is a chronic inflammatory skin disease. The intradermal application of botulinum toxin (BT) has been studied as a therapeutic option for patients who struggle to manage flushing and/or persistent facial erythema. There is no standard protocol for BT application in rosacea. Objective: To evaluate the effectiveness of botulinum toxin application on erythematotelan-giectatic rosacea. Methods: Pilot study with case series. We applied intradermal BT in 10 patients with a diagnosis of rosacea and symptoms of persistent erythema and/or facial flushing. Patients received 10 to 15 injections per hemiface (1 unit of onabotulinum BT per injection) and 0 to 5 injections in the nasal region, totaling 25 to 35 units per patient. Results: Seventy-five percent of the patients presented a reduction in flush and erythema intensity. The follow-up time was three months, and no serious adverse events were observed. Conclusions: The therapeutic arsenal to control erythema and facial flushing of rosacea, especially refractory to the usual treatment, should consider the intradermal application of BT type A.http://www.surgicalcosmetic.org.br/Content/imagebank/pdf/v13/en_v13a19.pdferythemarosaceaflushingbotulinum toxins |
| spellingShingle | Jaqueline Barbeito de Vasconcellos Isabele Oliveira Santos Daniela Alves Pereira Antelo Use of botulinum toxin for rosacea: a pilot study Surgical & Cosmetic Dermatology erythema rosacea flushing botulinum toxins |
| title | Use of botulinum toxin for rosacea: a pilot study |
| title_full | Use of botulinum toxin for rosacea: a pilot study |
| title_fullStr | Use of botulinum toxin for rosacea: a pilot study |
| title_full_unstemmed | Use of botulinum toxin for rosacea: a pilot study |
| title_short | Use of botulinum toxin for rosacea: a pilot study |
| title_sort | use of botulinum toxin for rosacea a pilot study |
| topic | erythema rosacea flushing botulinum toxins |
| url | http://www.surgicalcosmetic.org.br/Content/imagebank/pdf/v13/en_v13a19.pdf |
| work_keys_str_mv | AT jaquelinebarbeitodevasconcellos useofbotulinumtoxinforrosaceaapilotstudy AT isabeleoliveirasantos useofbotulinumtoxinforrosaceaapilotstudy AT danielaalvespereiraantelo useofbotulinumtoxinforrosaceaapilotstudy |